Gazyva (obinutuzumab)

September 6, 2019

Gazyva-Revlimid Effective for Certain Patients with Relapsed or Refractory Follicular Lymphoma, Trial Suggests

News

A combination of Gazyva (obinutuzumab) and Revlimid (lenalidomide) is effective for some patients with follicular lymphoma who failed prior treatments, including those with early relapses, according to a Phase 2 ... Read more

January 9, 2019January 31, 2019

First-line Imbruvica-Gazyva Therapy Extends Survival Without Disease Progression in CLL/SLL Patients, Phase 3 Study Shows

News

First-line treatment with Imbruvica (ibrutinib) plus Gazyva (obinutuzumab) significantly extends the time patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) live without cancer progression, and it also increases their ... Read more

October 23, 2018

FDA Grants Priority Review to Imbruvica-Gazyva Combo for First-line Treatment of CLL/SLL

News

The U.S. Food and Drug Administration has granted priority review to AbbVie‘s application seeking the approval of Imbruvica (ibrutinib) plus Gazyva (obinutuzumab) for patients with chronic lymphocytic leukemia or small lymphocytic ... Read more

August 8, 2018

Gazyva-Revlimid Combo Shows Promise for Follicular Lymphoma Patients in Clinical Trial

News

Gazyva (obinutuzumab) with Revlimid (lenalidomide) — a combination called Galen — is a potentially safe and effective treatment for relapsed or refractory follicular lymphoma, with over 60% of patients responding to treatment, ... Read more

August 3, 2018

Gazyva Infusion Could Be Shorter for Some NHL Patients, Study Finds

News

Shortening the time needed for an infusion of Gazyva (obinutuzumab) did not affect the safety of Japanese patients with previously untreated CD20-positive B-cell non-Hodgkin’s lymphoma, a new study shows. “Safety, tolerability ... Read more

February 10, 2017February 10, 2017

Canada OKs Gazyva-based Therapy for Follicular Lymphoma When Rituxan Fails

News

Canada’s medical regulatory agency has approved a Gazyva-based combo therapy for follicular lymphoma patients whose disease progressed either while or after they were treated with a Rituxan-based regimen. The therapy ... Read more

January 27, 2017

Combining Immunotherapy with Gazyva Seen to Boost Anti-tumor Activity

News

The effect of Gazyva (obinutuzumab) — a first line treatment for follicular lymphoma and leukemia patients — is significantly enhanced when combined with drugs that activate the immune system via the Toll-like receptor ... Read more

December 9, 2016December 9, 2016

Gazyva Shown to Outperform Rituxan in Phase 3 Trial in Follicular Lymphoma Patients

News

Patients with follicular lymphoma may soon have a new treatment option, as Genentech recently demonstrated that Gazyva (obinutuzumab) improved survival times without disease progression compared to standard treatment with Rituxan (rituximab). ... Read more